About this trial
Chronic inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are characterized by chronic immune-mediated inflammation primarily affecting the gastrointestinal tract. Venous and arterial thromboembolic events are significant extra-intestinal manifestations of IBD, but their pathogenic mechanisms are not fully understood. IBD patients have double the risk of venous thromboembolism (VTE) compared to the general population, with particularly high risk in pediatric patients, and an increased mortality rate. They also face a higher risk of early atherosclerosis and future cardiovascular events, such as myocardial infarction, ischemic stroke, and peripheral artery disease. The prevalence of thromboembolic events in IBD ranges from 1.3% to 7.7%, with venous events at around 5% and ischemic heart disease, cerebrovascular disease, and peripheral artery disease at 1-2%.
Eligibility criteria
Qualifiers
Diagnosis of IBD (both CD and UC, both in active and quiescent stages of disease)
Age > 18 years
Signature of informed consent
Disqualifiers
Other inflammatory states other than IBD (e.g., neoplasm, autoimmune diseases, liver cirrhosis)
Age < 18 years
Pregnant woman
Lack of informed consent
Trial design
Treatments tested in this trial
- examinations